Erratum to JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer


Published in:
Breast Cancer Research

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
Copyright 2017 the authors.
This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Erratum to: JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer

Yi Fang Lee¹, Lance David Miller², Xiu Bin Chan¹, Michael A. Black⁶, Brendan Pang³, Chee Wee Ong³, Manuel Salto-Tellez⁴, Manuel Salto-Tellez⁴, Edison T. Liu⁷ and Kartiki V. Desai⁸*

Erratum

Main text: After the publication of this work [1] an error was noticed in Fig. 8. In the SMAD2P465/467 panel, the images for MCF-7 and MDA MB 231 cells were accidentally duplicated. The corrected figure is shown below. We apologize for this error, which does not affect the findings or conclusions of the article.

Author details

¹Clearbridge BioMedics Private Ltd, 81 Science Park Drive, Singapore, Singapore. ²Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA. ³Department of Pathology, National University Health System and National University of Singapore, S Lower Kent Ridge Road, Singapore 119074, Singapore. ⁴Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, UK. ⁵Cancer Science Institute, National University of Singapore, 28 Medical Drive, Singapore 117456, Singapore. ⁶Department of Biochemistry, Otago School of Medical Sciences, University of Otago, 710 Cumberland Street, Dunedin 9054, New Zealand. ⁷The Jackson Laboratory, Bar Harbor, ME 04609, USA. ⁸National Institute of Biomedical Genomics, 2 Netaji Subash Sanatorium (T.B. Hospital), Kalyani 741251, India.

Received: 6 March 2017 Accepted: 6 March 2017
Published online: 28 March 2017

Reference


* Correspondence: kd1@nibmg.ac.in

© The Author(s), 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 8 JMJD6 expression affects SMAD phosphorylation. Immunoblots show that the level of total SMAD2/3, phosphorylated SMAD2 and phosphorylated SMAD3 are decreased in MCF-7 J1-OE clones, and increased in JMJD6 siRNA-mediated knock-down in MCF-7 and MDA-MB231. The numbers next to the SMAD2/3P denote the expected sites of phosphorylation detected by the antibodies. N.S. denotes non-specific bands from the blots which indicate equal loading of the protein lysates.